“It seems like COVID-19 now is the only disease present on Earth”: living with a rare or undiagnosed disease during the COVID-19 pandemic

Meghan C. Halley, Talia Stanley, Jay Maturi, Aaron J. Goldenberg, Jonathan A. Bernstein, Matthew T. Wheeler and Holly K. Tabor

PURPOSE: Patients with rare and undiagnosed diseases (RUDs) face significant health challenges, which may be exacerbated during the COVID-19 pandemic. The goal of this study was to identify specific impacts of the pandemic on RUD patients, and targets for improving support and health-care access.

METHODS: We conducted an online survey of RUD patients and their family members from 21 April to 8 June 2020, recruited from 76 Facebook groups for RUDs. Questions assessed patient characteristics and impacts of the pandemic on RUD diagnosis and management.

RESULTS: Respondents (n = 413), including 274 RUD patients and 139 family members, were predominantly female and white, though income varied. Impacts of the pandemic included (1) barriers to accessing essential health care, (2) specific impacts of restrictive COVID-19 visitation policies on ability to advocate in health-care settings, (3) uncertainty and fear regarding COVID-19 risk, (4) exacerbated physical and mental health challenges, (5) magnified impacts of reduced educational and therapeutic services, and (6) unexpected positive changes due to the pandemic.

CONCLUSION: There are specific, serious challenges affecting RUD patients and families during the COVID-19 pandemic. There is an urgent need to develop approaches to mitigate these challenges both during and beyond the pandemic.

INTRODUCTION

The COVID-19 pandemic has dramatically impacted communities across the United States, with the most severe impacts on specific subgroups, including racial/ethnic minorities and individuals with disabilities. Among those affected are the 30 million patients living with rare and undiagnosed diseases (RUDs). For these patients, medical complexity coupled with diagnostic and/or prognostic uncertainty make navigating health care challenging in the best of times, and these challenges may be exacerbated during the pandemic.

Although there are approximately 7,000 rare diseases, patients grappling with RUDs share many challenges. RUD patients typically undergo extensive medical testing as part of their diagnostic odysseys, after which an estimated 50% remain undiagnosed. Even when diagnosed, most rare diseases lack effective treatments, leaving many RUD patients reliant on clinical research as their primary source of therapy or for achieving a long-sought diagnosis. However, many clinical research studies were halted as a result of the COVID-19 pandemic.

RUD patients, and particularly pediatric patients, also often rely on diverse educational and therapeutic services, including those delivered through schools, which are essential but not easily translated to remote platforms. Prolonged stay-at-home orders therefore have the potential to dramatically impact the health of this population. At the same time, these patients are, by definition, grappling with complex health conditions that may create additional vulnerabilities to COVID-19 infection. This tension between increased needs and increased risks raises complex ethical and policy questions regarding how best to ensure that essential services are accessible and sufficient to meet the needs of this vulnerable population.

The goal of this study was to explore the challenges facing RUD patients during the COVID-19 pandemic and to suggest targets for action to address these challenges.

MATERIALS AND METHODS

Recruitment

We conducted an online survey from 21 April to 8 June 2020 through Facebook groups for RUDs, identified using broad and targeted keywords. Broad keywords (e.g., “genetic disease”) were selected through a series of preliminary searches testing the number and types of groups identified by different keywords. Targeted keywords (e.g., “Aarskog syndrome”) were drawn from the National Organization of Rare Diseases (NORD) rare diseases database.

We confirmed that groups were focused on RUDs by cross-checking the group description with rare disease databases published by professional organizations, including NORD, Global Genes, Genetic and Rare Diseases Information Center, and Orphanet. Any disease identified as rare on any of these lists was considered a rare disease for the purpose of this study. We excluded any groups explicitly oriented to participants in countries other than the United States based on the group description. Once identified, a member of the study team contacted the group administrators through private Facebook message.

© The Author(s), under exclusive licence to the American College of Medical Genetics and Genomics 2021
main themes: (1) sudden and extreme barriers to accessing essential health care, (2) specific impacts of COVID-19 visitation policies on their ability to advocate in health-care settings, (3) uncertainty and fear regarding COVID-19 infection risk, (4) physical and mental health challenges exacerbated by the pandemic, (5) magnified impacts of reduced educational and therapeutic services, and (6) unexpected positive changes due to the pandemic.

1. Sudden and extreme barriers to accessing essential health care

Respondents described significant negative impacts on their access to health care during the pandemic, including to care that they felt was essential to their health and well-being.

I don’t have access to the necessary medical care I usually have. My feeding tube placement was canceled with no alternative ways to get nutrition…. It’s nearly impossible to contact my doctors, and even more difficult for them to be able to help me. (Patient with RUD)

Another respondent described a similar challenge to accessing needed care, stating, “Our youngest son [has]...reoccurring vision issues because of his rare disorder [that] haven’t been able to be treated (he was supposed to have a procedure scheduled)” (Family member).

This lack of access also exacerbated existing challenges faced by those who were actively seeking a diagnosis, and/or were medically unstable.

Our genetics [results] should have been back by now but we have yet to hear back from her neurologist…. After fighting for three years trying to get genetic testing done [this] is very frustrating in itself…. COVID-19 has put us at a standstill for something that is destroying my baby. Her health now seems like it is not essential or being treated as seriously as it should, and I am at the end of my rope. (Family member)

Respondents also described significant challenges to accessing medical supplies.

...[we have an] inability to get medical supplies that we order and pay for out of pocket. Either there’s a shortage or the prices have skyrocketed making it difficult to pay…. We are private caregivers but can’t get access to basic PPE supplies.
Table 1. Respondent demographics.

|                          | Self (n) | Self (%) | Family Member (n) | Family Member (%) | All (n) | All (%) |
|--------------------------|----------|----------|-------------------|-------------------|---------|---------|
| Self or Family Member    | 274      | 66.3%    | 139               | 33.7%             | 413     | 100.00% |
|                          |          |          |                   |                   |         |         |
| Year of birth            |          |          |                   |                   |         |         |
| Total responses          | 168      | 1972 (1944–2001) | 122    | 1981 (1973–1986) | 290     | 1976 (1944–2001) |
|                          |          |          |                   |                   |         |         |
| Education                |          |          |                   |                   |         |         |
| Less than high school    | 2        | 1.2%     | 0                 | 0.0%              | 2       | 0.7%    |
| High school or GED       | 22       | 12.7%    | 9                 | 7.1%              | 31      | 10.4%   |
| Some college             | 59       | 34.1%    | 30                | 23.8%             | 89      | 29.8%   |
| Bachelor’s degree        | 38       | 22.0%    | 49                | 38.9%             | 87      | 29.1%   |
| Advanced/graduate level coursework or degree | 52 | 30.1% | 38 | 30.2% | 90 | 30.1% |
| Total responses          | 173      | 100.0%   | 126               | 100.0%            | 299     | 100.0%  |
| Gender                   |          |          |                   |                   |         |         |
| Male                     | 24       | 13.9%    | 8                 | 6.3%              | 32      | 10.6%   |
| Female                   | 145      | 83.8%    | 115               | 89.8%             | 260     | 86.4%   |
| Other                    | 4        | 2.3%     | 5                 | 3.9%              | 9       | 3.0%    |
| Total responses          | 173      | 100.0%   | 128               | 100.0%            | 301     | 100.0%  |
| Income                   |          |          |                   |                   |         |         |
| Less than $50,000        | 54       | 34.4%    | 20                | 17.9%             | 74      | 27.5%   |
| 50–100                   | 45       | 28.7%    | 38                | 33.9%             | 83      | 30.9%   |
| 100–150                  | 30       | 19.1%    | 30                | 26.8%             | 60      | 22.3%   |
| 150+                     | 28       | 17.8%    | 24                | 21.4%             | 52      | 19.3%   |
| Total responses          | 157      | 100.0%   | 112               | 100.0%            | 269     | 100.0%  |
| Insuranceb               |          |          |                   |                   |         |         |
| Medicaid, CHIP, or other state-based program | 24 | 14.2% | 50 | 40.7% | 74 | 25.3% |
| Medicare                 | 41       | 24.3%    | 10                | 8.1%              | 51      | 17.5%   |
| Private insurance        | 102      | 60.4%    | 88                | 71.5%             | 190     | 65.1%   |
| Other health insurance   | 25       | 14.8%    | 11                | 8.9%              | 36      | 12.3%   |
| No health insurance      | 13       | 7.7%     | 6                 | 4.9%              | 19      | 6.5%    |
| Total responses          | 169      | 100.0%   | 123               | 100.0%            | 292     | 100.0%  |
| Raceb                    |          |          |                   |                   |         |         |
| White                    | 159      | 95.8%    | 112               | 94.1%             | 271     | 95.1%   |
| Black or African American| 0        | 0.0%     | 1                 | 0.8%              | 1       | 0.4%    |
| Asian or Pacific Islander| 3        | 1.8%     | 4                 | 3.4%              | 7       | 2.5%    |
| American Indian or Alaskan Native | 1 | 0.6% | 0 | 0.0% | 1 | 0.4% |
| Some other race          | 5        | 3.0%     | 4                 | 3.4%              | 9       | 3.2%    |
| Total responses          | 166      | 100.0%   | 119               | 100.0%            | 285     | 100.0%  |
| Hispanic                 |          |          |                   |                   |         |         |
| No                       | 155      | 93.9%    | 109               | 88.6%             | 264     | 91.7%   |
| Yes                      | 10       | 6.1%     | 14                | 11.4%             | 24      | 8.3%    |
| Total responses          | 165      | 100.0%   | 123               | 100.0%            | 288     | 100.0%  |

CHIP Children’s Health Insurance Program, IQR interquartile range.
*Total responses represents the total number of participants who completed a given question. Completion rates per question ranged from 65.1% to 100%.
**Demographic questions were asked at the end of the survey, which contributed to the lower completion rates for these questions.
***Respondents could select multiple responses.
Respondents described the fear of having to access medical care without a companion to act as their advocate.

...I have to rely on family members to ensure the health-care providers are taking all my diagnoses and medications into consideration for treatment. If they can't be with me, I can’t be sure that I will remember to question everyone involved in my health care. (Patient with RUD)

Parents of younger children expressed concern regarding policies that allowed only one parent in the hospital and limited options for taking turns at bedside.

It has been absolute hell, and from the bottom to the top there has been an appalling lack of compassion. Our previously pretty darn great hospital turned into a prison overnight. Not to mention that we were exposed to [COVID-19] for 5 [solid] days by a provider, yet we as parents were considered not safe enough to be with our own children. (Family member)

On the other hand, parents of adult children with RUDs expressed fears of their child being forced to navigate the health-care system alone. As one described, “I am also concerned that because he is 20, he will be in a situation that I won’t be able to advocate for him” (Family member).

While visitation policies were described as emotionally taxing, respondents also described them as adding difficulty to already complex medical decision-making. As one family member stated, “Having only one person at appointments creates stress and difficulty communicating with my husband what is going on with our daughter. My husband lacks a say in what goes on with her care and isn’t included in many decision[s] because he can’t be there” (Family Member).

3. Uncertainty and fear regarding COVID-19 risk

As illustrated in Table 3, approximately two-thirds of RUD patients had at least one risk factor for COVID-19, while one-third did not. Respondents’ perceptions of their risk for severe COVID-19 infection also varied. Some described uncertainty and frustration surrounding the lack of information about their specific risk of COVID-19 conferred by their RUD. As one family member described, “[It is] unclear whether my son is officially considered high risk and whether we should shield him and siblings…longer term.” On the other hand, some were extremely fearful that COVID-19 infection would have devastating consequences. As one family member described, “last year my son caught [human metapneumovirus], he spent 38 days in the hospital, the majority of those days in the PICU on a ventilator. I know he would not survive COVID.” A patient with an RUD simply stated, “If I become infected with [COVID-19] I will die.” Still others expressed their concerns in terms of the potential for COVID-19 to add to existing medical complexity.

Table 2. Characteristics of RUD patients described by family members.

| Number of RUD patients cared for | n   | %   |
|----------------------------------|-----|-----|
| One                              | 123 | 88.5%|
| Two                              | 11  | 7.9% |
| More than two                    | 5   | 3.6% |
| Total family member responses    | 139 | 100.0%|

| Patient's relationship to family member | n   | %   |
|----------------------------------------|-----|-----|
| Child                                  | 139 | 89.7%|
| Spouse/domestic partner                | 7   | 4.5% |
| Parent                                 | 4   | 2.6% |
| Other family member                    | 5   | 3.2% |
| Total patients described              | 155 | 100.0%|

| Patient age | n   | %   |
|-------------|-----|-----|
| Less than 1 year | 17  | 11.0%|
| 1–5 years    | 46  | 29.9%|
| 6–10 years   | 29  | 18.8%|
| 11–17 years  | 16  | 10.4%|
| 18 and older | 46  | 29.9%|
| Total patients described               | 154 | 100.0%|

| Lives in household of family member | n   | %   |
|-------------------------------------|-----|-----|
| Yes, full time                      | 141 | 94.0%|
| Yes, part time                      | 8   | 5.3% |
| No                                  | 1   | 0.1% |
| Total patients described            | 150 | 100.0%|

*includes data for first RUD patient and second RUD patient, if reported by family member. Detailed data were collected on a maximum of two RUD patients per caregiver.

*Data missing for one patient described by a family member.

*Data missing for 5 patients described by a family member.

to keep our rare sick loved one safe. (Family member)

Respondents also expressed concern that the primary method available to access health care during the pandemic—telemedicine—sometimes felt insufficient for managing an RUD. One family member stated that “[doctors’ appointments are less thorough via telemed[cine] than if he were able to see them in person” and another stated, “All doctors want to do telehealth. Due to this, they missed [diagnosing] [my child] with a life-threatening virus, and he turned blue and had to be taken by ambulance.” These challenges in access to care left many feeling that only COVID-19 patients were receiving health care. As one respondent summarized, “It seems like COVID-19 now is the only disease present on Earth” (Patient with RUD).

2. Specific impacts of COVID-19 visitation policies on their ability to advocate in health-care settings

When RUD patients were able to access health care, they and their family members expressed frustration with strict limitations on visitors, companions, and caregivers many health-care organizations instituted to reduce the presence of nonessential personnel.
I am worried that my son is more likely to experience severe effects from the virus should he catch it.... I am also concerned that if he were to experience lung damage, or arterial inflammation, or myocarditis the consequences of those side effects would be harder on him than on a heart healthy child. He is already dealing with a lifelong heart defect and any further permanent bodily harm to him would be more catastrophic for him than an otherwise healthy child because it would be compounded. (Family member)

Respondents also expressed fear that, should they contract COVID-19, health-care providers would not know how to care for them due to their RUD.

I’m very concerned that if I were to come into contact with COVID-19 I will not receive treatment quickly or as aggressively as I feel I would need it. Because I appear healthy, it might be difficult to get a doctor to understand all the problems with my tissues due
to long-term use of steroids, or the severity of my compromised immune system and multiple medications I take to suppress it for disease purposes. (Patient with RUD)

In response to this fear and uncertainty, some respondents described drastic measures of social isolation, for example, “My loved one is even afraid to go outside because of this virus. We encourage her to just let us take her for a walk or sit in our patio. She’s so afraid she’s going to catch it and not survive if she did” (Family member).

Respondents also expressed frustration over what they felt was a lack of a clear source of support or information specifically for RUD patients. As one family member stated, “There’s no cohesive leadership or organization that offers or reaches out to rare disease patients and their families with offers to help educate us or dampen down our worry and fears” (Family member).

4. Physical and mental health challenges exacerbated by the pandemic

Respondents described multiple ways in which the complex health challenges caused by their RUD were exacerbated by the pandemic. One patient with an RUD described how, “the stress of it is making my illness flare up [and] affecting my mental health,” and another stated that, “the stress of the pandemic brought me out of remission.” Similarly, another respondent explained that, “I have two boys who were well controlled in their epilepsy treatment who have had multiple breakthrough seizures due to the stress” (Family member).

The severity of the stress involved in accessing essential health care, when they could, was described as so extreme by some that they were considering forgoing treatment. As one respondent described, “I am still receiving monthly IVIG infusions, but the stress of those appointments...also has me questioning whether my mental health would be better off without it” (Patient with RUD). Respondents similarly considered whether they ought to stop certain treatments because the side effects of the treatments themselves could put them at higher risk of COVID-19. As one described, “I am seriously considering stopping chemotherapy treatment for [my RUD] to lower my risk of a poor outcome should I develop COVID-19, as [being immunocompromised] would no longer be an issue” (Patient with RUD).

Family members also described serious impacts on their own mental health due to the stress of caring for an RUD patient during the pandemic. After discussing how the RUD patient s/he cared for was struggling with the challenges of the pandemic, one family member described how, “we too feel stressed out, anxiety ridden, depressed and unsupported as a family of a sick rare disease loved one. We do our best to manage it so it doesn’t affect or add to the same feelings our sick loved one is experiencing” (Family Member).

5. Magnified impacts of reduced educational and therapeutic services

While school closures have presented challenges for families across the country, family members of children with RUDs described the magnifying effect of the school closures due to their children’s additional educational needs. Educational services for children with special needs are often provided through an Individualized Education Program (IEP), which may include not only adapted educational programming, but also a range of physical, occupational, speech, and/or behavioral therapies. Family members described how school closures impacted access to these additional therapeutic services, which were critical to their child’s continued development. As one described, “He is missing a lot of his important physical, occupational and speech therapy, and he has significant delays and needs to get ready for kindergarten.” Another family member stated, “To me so far the biggest impact on my child has been the drastically reduced communication with teachers and therapists (usually multiple sessions per week)” (Family Member).

Family members also described the particular challenges of translating special education to remote platforms. As one respondent described, “…they haven’t been able to receive direct services for their academic IEP. All classes were switched to virtual, which isn’t conducive to special needs learning” (Family member).

6. Unexpected positive impacts of the pandemic

While respondents primarily focused on the challenges presented by the pandemic, some did describe unexpected positive changes in their ability to manage their RUD. Respondents described how the increased infection prevention measures taken by the general public have made them feel safer.

Now I think that going to the grocery store is more safe for me, [with] people keeping distance and [disinfecting] their hands, I really think we should do this all of the time. So actually the COVID-19 has been sort of a blessing for me. (Patient with RUD)

Respondents also described how the pandemic removed barriers to alternative work arrangements that actually made it easier to manage their RUD while working.

I just discovered I’m twice as efficient when working completely remotely [because I] haven’t caught a single virus since [the] shutdown almost 3 months ago, when I normally am constantly battling viruses. I’m one of the people who has zero desire to go back to “normal,” as it was never working for me anyway. (Patient with RUD)

Further, in contrast to respondents who raised concerns about telemedicine, some respondents described how the pandemic had removed some longstanding barriers in access to health care.

Insurance would not cover telemedicine in our state so [doctors] did not provide it before. Now instead of having to drive 7 1/2 hours one way to see my specialists for 45 minutes or less I can use a computer to connect and get labs or tests done locally. A huge blessing. (Patient with RUD)
DISCUSSION
This study provides a window into the experiences of RUD patients during the COVID-19 pandemic. Our results suggest that the pandemic is exacerbating longstanding challenges already faced by RUD patients (e.g., further extending an already long diagnostic odyssey) and also introducing new elements to these existing challenges (e.g., new limits on caregiver support impacting advocacy needs). While some aspects of these challenges may be shared by other patient populations grappling with complex health conditions, others may be specific to RUD patients. For example, while there is understandable enthusiasm for expansion of telehealth as a way of increasing health-care access for patients during the pandemic, our results suggest that telehealth may have significant limitations for very complex patients requiring coordination across multiple specialties, such as those with RUDs. In addition, while the impacts of COVID-19 visitation policies and their consequences have been examined in the context of intensive care unit (ICU) care of COVID-19 patients, RUD patients’ complex health challenges require increased advocacy even when accessing routine care. On the other hand, the limited literature in other patient groups indicates that those grappling with complex health conditions, such as cancer, during the pandemic also are at risk for serious mental health challenges, such as those described by our respondents. Our qualitative data further suggest that the anxiety caused by the pandemic may be leading some RUD patients to forgo treatment altogether, with potentially catastrophic implications for their already complex health. Similarly, while closure of schools has impacted countless families in myriad ways, for children with special needs—including many RUD patients—these closures have resulted in the reduction of critical therapeutic services, many of which do not easily translate to remote platforms. The insights of RUD patients and their families may also suggest challenges faced by other patients and families, beyond the already large RUD community.

Addressing these issues will require urgent action and attention to both new and chronic challenges faced by the RUD community. Addressing these needs quickly is important, given the rapidly changing landscape of COVID-19 mitigation strategies, evolving school reopening plans, and the development of vaccination and treatment approaches. On the other hand, our results suggest that the pandemic has exacerbated longstanding challenges in research and clinical care for RUD patients. As we face the short- and long-term implications of the pandemic, we must take into account the experiences of RUD patients to ensure that we address—rather than exacerbate—existing disparities for this large and complex patient population.

Potential targets include the development of policies and approaches recognizing the specific needs of RUD patients. For example, clinical settings could develop methods for identifying RUD patients within health-care systems and creating policy exceptions for those with increased advocacy needs. They could support coordinated telehealth planning across specialties to ensure that RUD patients can reap the benefits of expanded telehealth while ensuring that their complex health conditions are sufficiently monitored, and that they know when they need in-person care. This includes a need to explicitly reassure RUD patients that in-person care can be delivered safely and, in the case of COVID-19 treatment, with careful consideration of a patient’s RUD. Further, any efforts toward a multidisciplinary “one stop” model of highly coordinated care that can individually tailor care and integrate medical and social support needs is likely to improve outcomes for RUD patients both during and well beyond the pandemic.

Research institutions should consider research focused on diagnosis of undiagnosed patients when crafting their research guidelines in the midst of the ongoing pandemic. For example, the current Stanford School of Medicine guidelines explicitly identify “research that obtains critical, in-person observations or laboratory measures on vulnerable patients or populations where not obtaining these observations could negatively impact patient outcomes, safety or care,” as the highest priority for restarting, together with treatment studies. Johns Hopkins University’s research reopening plan similarly emphasizes that studies with the potential for direct clinical benefit to patients should be prioritized. While the language in these policies suggests that studies focused on RUD diagnoses would likely be included, further research is needed to understand how various institutions are approaching this issue.

RUD advocacy groups can use these data to further develop support mechanisms for RUD patients and families to address their pandemic-related concerns. For example, NORD has a number of COVID-19 specific resources for RUD patients, though our findings suggest further outreach may be needed. In addition, as nearly half of all patients in our sample identified as having a disability, the RUD community may benefit from COVID-19 resources designed for the disability community, such as those provided by the American Association on Health and Disability.

Our study has a number of limitations. As is common in online survey research using similar methods, our response rate cannot be empirically determined but is likely low given our broad dissemination strategy. However, our approach did allow us to include patients from a large number of RUD groups, at least partially addressing a longstanding challenge in understanding the shared experiences of the RUD community. It is possible that certain segments of the RUD community are overrepresented in our sample due to a variety of factors, including receptiveness of individual Facebook group administrators to participation. Further research in a representative sample of RUD patients would be needed to confirm generalizability and to examine the frequency and variability of these themes within the RUD community. In addition, women are overrepresented in our study, race/ethnic minority patients are underrepresented, and non-English-speaking patients are not included. Given the known disparities in COVID-19 impacts particularly for racial/ethnic minority groups, their perspectives are key and require attention. Undiagnosed patients also are underrepresented, and our ongoing research suggests that undiagnosed patients are less likely to have a specific rare disease group with which they identify. This survey also was conducted at one time point, and the experiences of RUD patients will likely evolve with the pandemic. In addition, although we focused on groups oriented to patients in the United States, we cannot be certain that all respondents were US residents. Finally, this study was focused on patient perspectives and lacks insights from health-care providers and administrators. Further research should examine the perspectives of other stakeholders to provide a fuller picture of the challenges facing RUD patients and potential mitigation strategies to improve care for this population during and after the pandemic.

Conclusion
COVID-19 is both creating new challenges and exacerbating existing challenges for RUD patients. Some of these challenges are specific to this population, while others may be shared by other patient groups. As the pandemic continues, creativity and flexibility will be critical to ensuring that RUD patients receive the care they need to manage their complex conditions. Health-care providers and institutions must work with advocacy organizations, patients, and families to assess emerging needs, improve access—including through the thoughtful use of telehealth—and consider unique advocacy needs when crafting new visitation policies. Research institutions should also ensure that ongoing research for RUD diagnosis and treatment is safely restarted and continued, as for other health conditions, such as cancer. Though the RUD community is medically heterogeneous, identifying their shared needs and proactively addressing them is essential, perhaps now more than ever, to ensure that these patients’ already challenging relationship with the medical community is not further compromised.
DATA AVAILABILITY
Materials, data sets, and protocols utilized in the acquisition of the data presented in this paper may be made available by the corresponding author upon request.

Received: 14 August 2020; Revised: 4 December 2020; Accepted: 7 December 2020; Published online: 8 January 2021

REFERENCES
1. Savin, K., Guidry-Grimes, L. Confronting disability discrimination during the pandemic. The Hastings Center. https://www.thehastingscenter.org/confronting-disability-discrimination-during-the-pandemic/ (2020).
2. Fink, S. U.S. civil rights office rejects rationing medical care based on disability, age. The New York Times. https://www.nytimes.com/2020/03/28/us/coronavirus-disabilities-rationing-ventilators-triage.html (2020).
3. Folkers, K. M. Coronavirus response is insufficient for vulnerable New Yorkers. The Hastings Center. https://www.thehastingscenter.org/coronavirus-response-is-insufficient-for-vulnerable-new-yorkers/ (2020).
4. Haffner, M. E., Whitey, J., & Moses, M. Two decades of orphan product development. Nat. Rev. Drug Discov. 1, 821–825 (2002).
5. Genetic and Rare Diseases Information Center. FAQs about rare diseases. https://rarediseases.info.nih.gov/diseases/pages/31/faqs-about-rare-diseases (2019).
6. Sanford Research. Pediatrics and rare diseases. https://research.sanfordhealth.org/fields-of-research/pediatrics-and-rare-diseases (2019).
7. Nutt, S. & Limb, L. Survey of patients’ and families’ experiences of rare diseases reinforces calls for a rare disease strategy. Social Care Neurodisabil. 2, 195–199 (2011).
8. von der Lippe, C., Diesen, P. S. & Feragen, K. B. Living with a rare disorder: a systematic review of the qualitative literature. Mol. Genet. Genomic Med. 5, 758–773 (2017).
9. Bogart, K. R. & Invin, V. L. Health-related quality of life among adults with diverse rare disorders. Orphanet J. Rare Dis. 12, 177 (2017).
10. Spillmann, R. C. et al. A window into living with an undiagnosed illness: illness narratives from the Undiagnosed Diseases Network. Orphanet J. Rare Dis. 12, 71 (2017).
11. Macnamara, E. F. et al. Cases from the Undiagnosed Diseases Network: the continued value of counseling skills in a new genomic era. J. Genet. Couns. 28, 194–201 (2019).
12. Shashi, V. et al. The utility of the traditional medical genetics diagnostic evaluation in the context of next-generation sequencing for undiagnosed genetic disorders. Genet. Med. 16, 176–182 (2014).
13. Ledford, H. Coronavirus shuts down trials of drugs for multiple other diseases. Nature. 580, 15–16 (2020).
14. Technology Networks. The global impact of COVID-19 on clinical trials and the way forward. Drug discovery from Technology Networks. https://www.technologynetworks.com/drug-discovery/blog/the-global-impact-of-covid-19-on-clinical-trials-and-the-way-forward-333652 (2020).
15. Chen, J. Covid-19 has shuttered scientific labs. It could put a generation of researchers at risk. STAT News. https://www.statnews.com/2020/05/04/coronavirus-lab-shutdowns-impact-on-scientists-research-delays/ (2020).
16. Fierce Pharma. Restarting research in the wake of COVID-19: the “new normal” for sites. https://www.fiercepharma.com/sponsored/restarting-research-wake-covid-19-new-normal-for-sites (2020).
17. ASCO Post. Half of surveyed cancer researchers report their work is on hold due to the COVID-19 pandemic. https://www.ascopost.com/news/may-2020/half-of-surveyed-cancer-researchers-report-their-work-is-on-hold-due-to-the-covid-19-pandemic/ (2020).
18. National Organization for Rare Disorders. Rare disease information. https://rarediseases.org/for-patients-and-families/information-resources/rare-disease-information/ (2020).
19. National Organization for Rare Disorders. List of rare disease information. https://rarediseases.org/for-patients-and-families/information-resources/rare-disease-information/ (2020).
20. Global Genes. Rare list. https://globalgenes.org/rare-list/ (2020).
21. Genetic and Rare Diseases Information Center. Browse A-Z. https://rarediseases.info.nih.gov/diseases/browse-by-first-letter (2020).
22. Orphanet. Diseases list. https://www.orpha.net/consor/cgi-bin/Disease_Search_List.php?lng=en (2020).
23. United States Census Bureau. 2020 Census. https://2020census.gov (2020).
24. Nelson, L. M. et al. US public concerns about the COVID-19 pandemic from results of a survey given via social media. JAMA Intern. Med. 180, 1020 (2020).
25. Centers for Disease Control and Prevention. Coronavirus disease 2019: people with certain medical conditions. https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html (2020).
26. R Core Team. R: a language and environment for statistical computing. R Foundation for Statistical Computing. http://www.R-project.org/ (2017).
27. Microsoft Corporation. Microsoft Excel. https://office.microsoft.com/excel (2020).
28. Miles, M. B., Huberman, A. M., Saldana, J. Qualitative Data Analysis: A Methods Sourcebook. Fourth edition. Thousand Oaks, CA: SAGE. 2020.
29. McHugh, M. L. Interrater reliability: the kappa statistic. Biochem. Med. (Zagreb) 22, 276–282 (2012).
30. Hoffmann, D. A. Increasing access to care: telehealth during COVID-19. J. Law Biosci. 7, Issa043 (2020).
31. Andriot, E., Clarke, R. G. & Harding, M. Paved with good intentions: hospital visitation restrictions in the age of coronavirus disease 2019. Pediatr. Crit. Care Med. 21, e924–e926 (2020).
32. Wakam, G. K., Montgomery, J. R., Biesterveld, B. E. & Brown, C. S. Not dying alone—modern compassionate care in the Covid-19 pandemic. N. Engl. J. Med. 382, e68 (2020).
33. Wang, Y. et al. Epidemiology of mental health problems among patients with cancer during COVID-19 pandemic. Transl. Psychiatry 10, 263 (2020).
34. Garbe, A., Ogurlu, U., Logan, N. & Cook, P. Parents’ experiences with remote education during COVID-19 school closures. Am. J. Qualitative Res. 4, 45–65 (2020).
35. Nestler-Parr, S. et al. Challenges in research and health technology assessment of rare disease technologies: report of the ISPOR Rare Disease Special Interest Group. Value Health 21, 493–500 (2018).
36. Van Groenendael, S. et al. High quality, patient centred and coordinated care for Alström syndrome: a model of care for a ultra-rare disorder. Orphanet J. Rare Dis. 10, 149 (2015).
37. Schoen, C. et al. New 2011 survey of patients with complex care needs in eleven countries finds that care is often poorly coordinated. Health Aff. (Millwood) 30, 2437–2448 (2011).
38. Stanford Medicine. Spectrum: Stanford Center for Clinical and Translational Research. https://med.stanford.edu/spectrum.html (2020).
39. Johns Hopkins University. Coronavirus information: return to research. https://covidinfo.jhu.edu/jhu-2020-planning/return-to-research/ (2020).
40. National Organization for Rare Disorders. Home. https://rarediseases.org/ (2020).
41. American Association on Health and Disability. Resources for people with disabilities on COVID-19. AAHD. https://aahd.us/covid-19/ (2020).
42. Dorn, A., van, Cooney, R. E. & Sabin, M. L. COVID-19 exacerbating inequalities in the US. Lancet. 395, 1243–1244 (2020).

ACKNOWLEDGEMENTS
The authors thank the members of the Patient Engagement and Empowerment Resource of the Undiagnosed Diseases Network for feedback on the initial survey draft, and Emily Miller for technical support.

AUTHOR CONTRIBUTIONS
Conceptualization: M.C.H, H.K.T. Data curation: M.C.H, T.S., J.M. Formal analysis: M.C.H., A.G., H.K.T. Writing original draft: M.H., H.K.T. Writing review & editing: M.H., H.K.T.

ETHICS DECLARATION
All study procedures were approved by the Stanford University School of Medicine Institutional Review Board. Informed consent was required and obtained from all participants.

COMPETING INTERESTS
The authors declare no competing interests.

ADDITIONAL INFORMATION
The online version of this article (https://doi.org/10.1038/s41436-020-01069-7) contains supplementary material, which is available to authorized users.

Correspondence and requests for materials should be addressed to M.C.H.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.